contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


senzime-secures-additional-us-hospital-system-contracts

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Senzime operates in the medical technology industry and focuses on the development and manufacture of systems for monitoring and diagnostics in healthcare. The portfolio includes systems used to automate and measure the substances glucose and lactate in blood and tissues. The company's products are aimed at healthcare institutions and physicians. The operations are global. Senzime was founded in 1999 and is headquartered in Uppsala, Sweden.

Senzime

Uppsala, Sweden – Senzime AB today announced that it has secured new important US hospital system contracts including initial delivery of 60 next-generation TetraGraph neuromuscular monitoring...

<div class="mfn-preamble"><p><strong>Uppsala, Sweden – Senzime AB today announced that it has secured new important US hospital system contracts including initial delivery of 60 next-generation TetraGraph neuromuscular monitoring systems to an Integrated Delivery Network (IDN) with strong presence in the Northeastern region.</strong></p></div><div class="mfn-body"><p><em>“This demonstrates the power of our solutions and the capabilities we have in meeting demands of large US hospital systems. The new IDN contract was awarded following a competitive evaluation including EMG and legacy AMG technologies, showcasing once again how our technology is emerging as the new gold-standard. The contract represents an opportunity for recurring sensor revenue coming from more than 20,000 patients every year, when fully implemented”</em>, says Philip Siberg, CEO of Senzime.<br>&nbsp;<br>Senzime’s TetraGraph system is used by anesthesiologists in more than 500 leading hospitals worldwide. Its proprietary technology meets the requirements of the recently published US and European guidelines recommending neuromuscular monitoring of all patients receiving paralytic drugs. TetraGraph is powered by EMG-technology and helps anesthesiologists accurately determine the correct dose of paralytic drugs and their antagonists and determines when patients breathing function has safely recovered post-surgery.</p></div><div class="mfn-footer mfn-contacts mfn-8e21f6378646"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p>Philip Siberg, CEO of Senzime AB<br>Phone: +46 (0) 707 90 67 34, e-mail:&nbsp;<a rel="noopener" href="mailto:philip.siberg@senzime.com">philip.siberg@senzime.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/6f73f94f-1dd1-4972-b614-865d1f843636/senzime-secures-additional-us-hospital-system-contracts.pdf" class="mfn-generated mfn-primary">Senzime secures additional US hospital system contracts</a></p></div>

Senzime secures additional US hospital system contracts

Voittajan kirous

Yhdysvallat velkaantuu ja dollari heikkenee: Onko eurosta turvasatamaksi?

Pörsseissä ongitaan taas uusia huippuja, politikointi päällä Fed-valinnoissa

Pienyhtiöt ovat jääneet isoista jälkeen alkuvuoden nousumarkkinassa

Euroopan talouskasvu murrosvaiheessa: Mikä vielä pidättelee Eurooppaa?